<?xml version="1.0" encoding="UTF-8"?>
<p>The proportion of patients in each group requiring changes in systemic therapy for control of chronic GvHD at 3 years after first-line treatment was 17% for the UCB group, 25% for the Haplo/PTCY groups and 39% for the 1-mMUD group, and was significantly lower for the UCB group than for the 1-mMUD group [HR 0.30 (95% CI: 0.1-0.8), 
 <italic>P</italic>=0.01] (
 <xref ref-type="fig" rid="f4-1040835">Figure 4A</xref> and 
 <xref rid="t3-1040835" ref-type="table">Table 3</xref>).
</p>
